---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Cost-effectiveness evidence"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Cost-effectiveness evidence. Topics: Company statements on pricing and launch timing of ficerafusp alfa, Company estimate of the market for first-line treatment of recurrent or metastatic HPV-negative disease, Cost-effectiveness of first-line pembrolizumab regimens from a United States payer perspective, Cost-effectiveness of first-line pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy, and 1 further topic. 6 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics/cost-effectiveness"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Cost-effectiveness evidence

<a id="heading-4.1"></a>

## 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

### Summary

No budget impact model, cost-effectiveness analysis, or health technology assessment of ficerafusp alfa was found, and no price for it has been published. Bicara states that ficerafusp alfa “may be priced at a significant premium over competitive products if any have been approved by then”, and its presentation describes first-line recurrent or metastatic HPV-negative HNSCC as “a global commercial opportunity of ~$5B+ annually by 2030”. Three published U.S. payer models address first-line comparators. Borse et al. (2022) used a three-state partitioned-survival model over 20 years with 3% annual discounting: pembrolizumab monotherapy was dominant versus the EXTREME regimen in the CPS ≥1 population, and pembrolizumab combination therapy was cost-effective versus EXTREME at $1769/QALY in the overall population. In the Markov model of She et al. (2022), pembrolizumab plus chemotherapy versus cetuximab plus chemotherapy yielded ICERs of $147876.14, $134237.84, and $153660.78 per QALY in the total, CPS ≥1, and CPS ≥20 populations. Ye et al. (2024), using a 15-year three-state partitioned survival model, found the EXTREME regimen cost-effective compared with nivolumab plus ipilimumab at a willingness-to-pay threshold of $150,000/QALY. None of these models includes ficerafusp alfa.

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm); [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4); [Borse et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35765888/); [She et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35483156/); [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10957979/)

<a id="topic-4.1-2"></a>

### Budget impact model, cost-effectiveness analysis, or health technology assessment of ficerafusp alfa

No evidence found.

<a id="topic-4.1-3"></a>

### Company statements on pricing and launch timing of ficerafusp alfa

> “In November 2026, we announced that FORTIFI-HN01 reached substantial enrollment to enable an interim analysis in mid-2027 to support a potential approval and U.S. launch in 2028.”
> “Even if ficerafusp alfa achieves marketing approval, it may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-4.1-4"></a>

### Company estimate of the market for first-line treatment of recurrent or metastatic HPV-negative disease

> “1L R/M HPV-negative HNSCC represents a global commercial opportunity of ~$5B+ annually by 2030 in a setting of profound unmet need”
> “A $5B+ annual global market that FICERA is built to lead, and to grow”
> “projected annual global HNSCC sales by 2030”

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="topic-4.1-5"></a>

### Cost-effectiveness of first-line pembrolizumab regimens from a United States payer perspective

> “Using public drug prices, from a US payer perspective, we evaluated the cost-effectiveness of each pembrolizumab regimen vs. cetuximab + platinum+5-FU (EXTREME regimen, trial comparator), cisplatin + docetaxel + cetuximab (TPEx regimen), cisplatin + paclitaxel, and platinum+5-FU.”
> “First-line pembrolizumab monotherapy in patients with CPS ≥1, and pembrolizumab combination therapy in the overall R/M HNSCC population is cost-effective from the perspective of the US payers.”

Source: [Borse et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35765888/)

<a id="topic-4.1-6"></a>

### Cost-effectiveness of first-line pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy

> “First-line treatment with pembrolizumab or pembrolizumab plus chemotherapy are cost-effective strategies compared with cetuximab plus chemotherapy when the value of willingness-to-pay (WTP) was $150000 per QALY for the total and PD-L1 CPS ≥ 1 populations with recurrent or metastatic HNSCC.”

Source: [She et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35483156/)

<a id="topic-4.1-7"></a>

### Cost-effectiveness of first-line nivolumab plus ipilimumab versus the EXTREME regimen

> “The EXTREME regimen is cost-effective compared with nivolumab plus ipilimumab for all randomly assigned populations with R/M SCCHN at a WTP threshold of $150,000/QALY from the payer's perspective in the United States.”

Source: [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10957979/)

Additional sources: [Fraslin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40848743/); [Li et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12083786/)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
